生物铁-SMBR法处理印染废水

为提高膜生物反应器（SMBR）的处理效果,在一体式膜生物反应器中加入氢氧化铁絮体,将生物铁法与一体式膜生物反应器相结合,提出了生物铁SMBR法.利用生物铁-SMBR法处理模拟印染废水,并与PAC-SMBR及普通SMBR进行平行对比试验,结果表明,生物铁-SMBR法在提高处理效果方面具有明显优势.在其容积负荷比普通SMBR平均高25%的情况下,生物铁-SMBR法对COD、染料、NH3-N（氨-氮）的去除率分别高1.0%、9.5%、5.2%.与普通SMBR相比,PAC-SMBR也能够提高对印染废水的处理效果.在其容积负荷比后者平均高6%的情况下,对COD、染料、NH3-N的去除率分别比后者高0.6%、4.0%、5.3%.     

沙棘果汁饮料的研制

以沙棘鲜果为原料进行沙棘果汁饮料配方研究,实验表明沙棘果汁饮料的最佳配方为:沙棘原汁10％,糖8％,CMC 0．08％,香精0．10％,苹果酸0．10％。     

Superexchange Ferromagnetic Coupling and Thermodynamic Features of the La2FeCoO6 Semiconductor

Journal of Low Temperature Physics - Ab initio calculations of the electronic and thermodynamic properties for the oxide ferrocobaltite of the perovskite-type La2FeCoO6 are reported. The...     

Impact of lean interventions on time buffer reduction in a hospital setting

This paper focuses on performance changes stemming from a series of lean interventions in a medical laboratory. This research is one of the first to link a series of lean interventions and performance over time. In a mixed-method case study, six years of patient-related throughput data, retrieved from a laboratory computer database, are analysed. Three distinct periods with significant differences in throughput time performance can be distinguished. Semi-structured interviews were held to investigate the lean interventions preceding the performance changes. Given the long-term nature of the study, the event history calendar method was applied to enhance the respondents’ recall and reliability. A single lean intervention, among the hundreds that took place, was supposed to cause the main reduction in throughput times. It concentrated on improving process flow through the removal of batching, a source of artificial variability. A later major intervention, the introduction of flow-focused machinery, had mixed effects and initial performance gains were not sustained. The results show that ongoing series of interventions do not always lead to ongoing performance improvements in terms of throughput times but support theories emphasising the importance of variability reduction.     

Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: a Pediatric Oncology Group study

The presenting characteristics and survival of children with the newly recognized transitional cell pre-B immunophenotype of acute lymphoblastic leukemia (ALL) are compared with those of children with pre-B ALL to determine the clinical significance of the new phenotype. Patients with transitional pre-B ALL (n = 17), defined by lymphoblasts expressing cytoplasmic and surface mu heavy chains without kappa or lambda light chains, have lower initial leukocyte counts (p = 0.02) and a higher frequency of DNA indexes > 1.16 (p < 0.001) than patients with pre-B ALL (n = 501), whether or not cases with the unfavorable prognostic (1;19) translocation are included in the analysis. Patients with transitional pre-B ALL lack FAB L3 morphology, bulky extramedullary disease, surface kappa or lambda chains, and the (8;14), (8;22), and (2;8) translocations, features that characterize the syndrome of B-cell ALL. The 4-year relapse-free survival result for children with transitional pre-B ALL appears better than that for children with pre-B ALL (93.3 +/- 17% versus 72.9% +/- 4.6%), but this difference is not statistically significant. We conclude that patients with transitional pre-B ALL have a very favorable prognosis in the context of the therapy used in this study.     

Trisomy 21 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study (8602)

Of 1,036 children with newly diagnosed non-T, non-B acute lymphoblastic leukemia (ALL) and a demonstrated cytogenetic abnormality treated on the frontline Pediatric Oncology Group (POG) therapeutic trial 8602, there were 33 patients with trisomy 21 as the sole abnormality. Of these 33, 14 had Down syndrome (DS). Although the non-DS (NDS) trisomy 21 cases tended to be older than the DS cases, there were no other significant differences in clinicobiologic features nor in treatment outcomes between the DS and NDS groups, nor between the entire trisomy 21 group and the other chromosome abnormality group. Among NDS patients with +21 and one additional abnormality, +X, +16, -20, and structural abnormalities involving 6q or 12p were common findings. Kaplan-Meier event-free survival (EFS) curves showed a 4-year EFS of 80% (SE, 12%) in NDS trisomy 21 cases, 71% (SE, 22%) in DS cases with trisomy 21 as the sole abnormality, and 69% (SE, 2%) in cases with other chromosome abnormalities. Trisomy 21 as a sole acquired abnormality in NDS patients suggests a good prognosis.